Corash L - Search Results

1

Resuscitative Strategies to Modulate the Endotheliopathy of Trauma: From Cell to Patient.

Wu F, Chipman A, Pati S, Miyasawa B, Corash L, Kozar RA. Wu F, et al. Among authors: corash l. Shock. 2020 May;53(5):575-584. doi: 10.1097/SHK.0000000000001378. Shock. 2020. PMID: 31090680 Free PMC article. Review.

2

Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.

Nussbaumer W, Amato M, Schennach H, Astl M, Chen CY, Lin JS, Corash L, Benjamin RJ. Nussbaumer W, et al. Among authors: corash l. Vox Sang. 2017 Apr;112(3):249-256. doi: 10.1111/vox.12489. Epub 2017 Feb 15. Vox Sang. 2017. PMID: 28198023

3

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6^o C.

Erickson A, Waldhaus K, David T, Huang N, Rico S, Corash L, Mufti N, Benjamin RJ. Erickson A, et al. Among authors: corash l. Transfusion. 2017 Apr;57(4):997-1006. doi: 10.1111/trf.13973. Epub 2017 Feb 1. Transfusion. 2017. PMID: 28150310

4

Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.

Dean CL, Hooper JW, Dye JM, Zak SE, Koepsell SA, Corash L, Benjamin RJ, Kwilas S, Bonds S, Winkler AM, Kraft CS. Dean CL, et al. Among authors: corash l. Transfusion. 2020 May;60(5):1024-1031. doi: 10.1111/trf.15739. Epub 2020 Mar 4. Transfusion. 2020. PMID: 32129478 Clinical Trial.

5

Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.

Infanti L, Holbro A, Passweg J, Bolliger D, Tsakiris DA, Merki R, Plattner A, Tappe D, Irsch J, Lin JS, Corash L, Benjamin RJ, Buser A. Infanti L, et al. Among authors: corash l. Transfusion. 2019 Nov;59(11):3350-3361. doi: 10.1111/trf.15511. Epub 2019 Oct 1. Transfusion. 2019. PMID: 31574181 Free PMC article.

6

The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model.

Corash L, Benjamin RJ. Corash L, et al. Transfusion. 2016 Mar;56 Suppl 1:S29-38. doi: 10.1111/trf.13530. Transfusion. 2016. PMID: 27001358 Review.

7

Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.

Aydinok Y, Piga A, Origa R, Mufti N, Erickson A, North A, Waldhaus K, Ernst C, Lin JS, Huang N, Benjamin RJ, Corash L. Aydinok Y, et al. Among authors: corash l. Br J Haematol. 2019 Aug;186(4):625-636. doi: 10.1111/bjh.15963. Epub 2019 May 30. Br J Haematol. 2019. PMID: 31148155 Free PMC article.

8

INTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without) clinical refractoriness in published studies.

Benjamin RJ, Corash L, Norris PJ. Benjamin RJ, et al. Among authors: corash l. Transfusion. 2020 Apr;60(4):881-882. doi: 10.1111/trf.15722. Transfusion. 2020. PMID: 32246477 No abstract available.

9

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione.

North AK, Mufti N, Sullivan T, Corash L. North AK, et al. Among authors: corash l. Transfusion. 2020 Feb;60(2):358-366. doi: 10.1111/trf.15662. Epub 2020 Jan 12. Transfusion. 2020. PMID: 31930533 Free PMC article.

10

Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.

Corash L. Corash L. Vox Sang. 1998;74 Suppl 2:173-6. doi: 10.1111/j.1423-0410.1998.tb05418.x. Vox Sang. 1998. PMID: 9704443 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters